Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Boundless Bio Inc (BOLD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.41+0.42%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BOLD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash to fund operations through second half of 2028 | Boundless Bio aims to extend its cash runway into the second half of 2028. | Intact | cash runway falls short of second half 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
BOLD is an early-stage, loss-making company rather than an established earnings compounder. Its thesis is in a watch state, with low confidence, weak recent performance, and elevated risk.
The evidence snapshot does not include valuation or market-expectation data, so whether the shares look cheap, fair, or expensive cannot be assessed. It does show that recent performance is well below the industry cohort, while the share reaction is recorded as up; the expectations gap is unclear.
Near term, results are likely to remain pressured: BOLD reported no revenue and a net loss of $13.6 million in 2026-Q1, while management is pursuing a major workforce reduction with limited evidence of savings so far. Management says its cash runway priority extends into the second half of 2028 and expects initial KOMODO-1 trial data within that runway, but neither the data nor the full effect of restructuring is yet established.
The multi-year thesis hinges on delivering initial proof-of-concept data from KOMODO-1 while preserving the stated cash runway. Near term, a guidance cut or further weakening in jobs data could add pressure; stronger earnings and guidance from sector bellwethers could support the Healthcare backdrop.
Over the next 1 to 3 years, BOLD remains a speculative clinical-development story with weak current fundamentals and important milestones still ahead. The evidence is limited, and the thesis depends on trial progress, cash discipline, and the impact of the restructuring. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Boundless Bio Inc's published investment case. The stated target is EPS improves from -$0.62 to better than -$0.5 next year. |
| Intact |
| EPS remains below -$0.7 in next fiscal year |
Diluted EPS: $-1.06 per share FY2026-Q2; GAAP. Published target: EPS improves from -$0.62 to better than -$0.5 next year. Target period is not explicitly aligned with this observation. Aug 7, 2026-1.06 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Implement workforce reduction of approximately 75% | The company plans a workforce reduction of about 75% to cut costs. | Intact | workforce reduction less than 75% or costs exceed $5M | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.93 → $-0.98 · observed estimates
$0.00B → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.93 | $0 | 1 / 1 |
| 2026-07-25 | $-0.93 | $0 | 1 / 1 |
| 2026-07-26 | $-0.93 | $0 | 1 / 1 |
| 2026-07-27 | $-0.93 | $0 | 1 / 1 |
| 2026-07-28 | $-0.93 | $0 | 1 / 1 |
| 2026-07-29 | $-0.93 | $0 | 1 / 1 |
| 2026-07-30 | $-0.93 | $0 | 1 / 1 |
| 2026-07-31 | $-0.93 | $0 | 1 / 1 |
| 2026-08-01 | $-0.93 | $0 | 1 / 1 |
| 2026-08-02 | $-0.93 | $0 | 1 / 1 |
| 2026-08-03 | $-0.93 | $0 | 1 / 1 |
| 2026-08-04 | $-0.93 | $0 | 1 / 1 |
| 2026-08-05 | $-0.93 | $0 | 1 / 1 |
| 2026-08-06 | $-0.93 | $0 | 1 / 1 |
| 2026-08-07 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-08 | $-0.93 | $0 | 1 / 1 |
| 2026-08-09 | $-0.93 | $0 | 1 / 1 |
| 2026-08-10 | $-0.93 | $0 | 1 / 1 |
| 2026-08-11 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-12 | $-0.98 | $0 | 1 / 1 |
| 2026-08-13 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-14 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-15 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-16 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-17 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-18 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-19 | $-0.93 | Unavailable | 1 / 0 |
| 2026-08-20 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-21 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-22 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-23 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-24 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-25 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-26 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-27 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-28 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-29 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-30 | $-0.98 | Unavailable | 1 / 0 |
| 2026-08-31 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-01 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-02 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-03 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-04 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-05 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-06 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-07 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-08 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-09 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-10 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-11 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-12 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-13 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-14 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-15 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-16 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-17 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-18 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-19 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-20 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-21 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-22 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-23 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-24 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-25 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-26 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-27 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-28 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-29 | $-0.98 | Unavailable | 1 / 0 |
| 2026-09-30 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-01 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-02 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-03 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-04 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-05 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-06 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-07 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-08 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-09 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-10 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-11 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-12 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-13 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-14 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-15 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-16 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-17 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-18 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-19 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-20 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-21 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-22 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-23 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-24 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-25 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-26 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-27 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-28 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-29 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-30 | $-0.98 | Unavailable | 1 / 0 |
| 2026-10-31 | $-0.98 | Unavailable | 1 / 0 |
| 2026-11-01 | $-0.98 | Unavailable | 1 / 0 |
| 2026-11-02 | $-0.98 | Unavailable | 1 / 0 |
| 2026-11-03 | $-0.98 | Unavailable | 1 / 0 |
| 2026-11-04 | $-0.98 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.